CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0030731: CarcinomaHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (9)


Name (Synonyms) Correlation
drug355 Control (albumin 5%) Wiki 0.71
drug169 Berzosertib Wiki 0.71
drug1604 nasopharyngeal Covid 19 RT-PCR Wiki 0.71
drug288 Carboplatin Wiki 0.71
drug1201 SLEDD with a L-MOD Wiki 0.71
drug435 Docetaxel Wiki 0.71
drug733 Laboratory Biomarker Analysis Wiki 0.71
drug361 Convalescent Plasma (anti-SARS-CoV-2 plasma) Wiki 0.50
drug357 Control group Wiki 0.41

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D002277 Carcinoma NIH 1.00
D011471 Prostatic Neoplasms NIH 0.71
D006528 Carcinoma, Hepatocellular NIH 0.71

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0012125 Prostate cancer HPO 0.71
HP:0001402 Hepatocellular carcinoma HPO 0.71

There are 2 clinical trials

Clinical Trials


1 A Phase 2 Study of M6620 in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer

This phase II trial studies how well berzosertib (M6620) and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving M6620, carboplatin and docetaxel may work better in treating patients with metastatic castration-resistant prostate cancer compared to carboplatin and docetaxel alone.

NCT03517969 Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma Stage IV Prostate Cancer AJCC v8 Drug: Berzosertib Drug: Carboplatin Drug: Docetaxel Other: Laboratory Biomarker Analysis
MeSH:Carcinoma Prostatic Neoplasms
HPO:Carcinoma Prostate cancer Prostate neoplasm

Primary Outcomes

Description: Defined by radiographic response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or prostate specific antigen [PSA] response of > 50%). Will be conducted using the Cochran-Mantel-Haenszel test, with one-sided p-value of =< 0.05 considered significant.

Measure: Response rate (complete response + partial response)

Time: Up to 2 years

Secondary Outcomes

Description: Assessed by Prostate Cancer Working Group (PCWG)3. PFS to be estimated with the Kaplan Meier methodology. Median and event-free rate at selected time points will be provided with 95% confidence interval.

Measure: Progression-free survival (PFS)

Time: From the time of randomization up to 2 years

Description: Assessed by PCWG2. PSA progression will be estimated with the Kaplan Meier methodology. Median and event-free rate at selected time points will be provided with 95% confidence interval. Comparison of time to PSA progression between arms will be conducted using the log-rank test.

Measure: Time to PSA progression

Time: From the time of randomization up to 2 years

Description: Assessed by RECIST 1.1. rPFS will be estimated with the Kaplan Meier methodology. Median and event-free rate at selected time points will be provided with 95% confidence interval.

Measure: Radiographic progression-free survival (rPFS)

Time: From the time of randomization up to 2 years

Description: Will be summarized according to treatment arm. For toxicity reporting, all adverse events will be graded and analyzed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Type of adverse events, intensity (grading), and attribution will be provided in a listing. All adverse events resulting in discontinuation, dose modification, and/or dosing interruption, and/or treatment delay of drug will also be summarized. Laboratory test results will be classified according to the CTCAE version 5.0.

Measure: Incidence of adverse events

Time: Up to 2 years

Other Outcomes

Description: OS will be estimated with the Kaplan Meier methodology. Comparison of OS between arms will be conducted using the log-rank test base on the intention-to-treat approach, where two treatment arms will be compared regardless of cross-over or any subsequent therapy.

Measure: Overall survival (OS)

Time: From the time of randomization up to 2 years

Description: Gene mutation frequencies and mean +/- standard deviation of quantitative biomarkers will be summarized by arm and in overall population at baseline and/or at end of study.

Measure: Gene mutation frequencies

Time: Baseline up to 2 years

2 Impact of COVID-19 Infection in Patients With Hepatocellular Carcinoma: An Ambispective Study Nestled in the CHIEF Cohort

Since December 2019, a new disease named COVID-19 linked to a new coronavirus, SARS-CoV2 has emerged in China in the city of Wuhan, Hubei province, spreading very quickly to all 5 continents, and responsible for a pandemic. France is the third most affected country in Europe after Italy and Spain. Groups of patients at a higher risk of developing a severe form of COVID-19 have been defined: this include patients with immunosuppressive disease as cancer or patients with advanced cirrhosis of the liver. Coronavirus liver injury had been described with SARS-CoV 1 and MERS-CoV. There is no data on liver damage associated with COVID-19 infection for compensated or decompensated cirrhotic patients. The objectives of this project are to estimate the incidence of COVID-19 in hepatocellular carcinoma population, both hospital and ambulatory, and to study the impact on the frequency of severe forms, the prognosis, but also liver function, and the management of hepatocellular carcinoma, in this context of pandemic

NCT04367805 Hepatocellular Carcinoma COVID-19 Diagnostic Test: nasopharyngeal Covid 19 RT-PCR
MeSH:Carcinoma Carcinoma, Hepatocellular
HPO:Carcinoma Hepatocellular carcinoma

Primary Outcomes

Description: Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France

Measure: Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France

Time: 6 months


HPO Nodes